We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bluebird bio Inc and Bristol-Myers Squibb Co recently reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.